Imatinib alone and in combination for chronic myeloid leukemia

Seminars in Hematology

Volumn 40, Issue 1, 2003, Pages 50-58

  Druker, Brian J ^a,b  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; IMATINIB;

ABDOMINAL PAIN; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; ARTHRALGIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CONSTIPATION; COUGHING; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG TARGETING; DYSPEPSIA; DYSPNEA; EDEMA; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; INSOMNIA; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NIGHT SWEAT; PAIN; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; RHINOPHARYNGITIS; RIGOR; SWEATING; TREATMENT PLANNING; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VOMITING; WEIGHT GAIN;

EID: 0037254419     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(03)70042-0     Document Type: Review

References (53)

1. Beran M, Cao X, Estrov Z, et al: Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res 4:1661-1672, 1998
2. Branford S, Rudzki Z, Walsh S, et al: High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99:3472-3475, 2002
3. Buchdunger E, Matter A, Druker BJ: Bcr-Abl inhibition as a modality of CML therapeutics. Biochim Biophys Acta 1551: M11-18, 2001
4. Carroll M, Ohno-Jones S, Tamura S, et al: CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL and TEL-PDGFR fusion proteins. Blood 90:4947-4952, 1997
5. Deininger MW, Goldman JM, Lydon N, et al: The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90:3691-3698, 1997
6. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002
7. Dorsey JF, Jove R, Kraker AJ, et al: The pyrido(2,3-d)pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res 60:3127-3131, 2000
8. Druker B, Kantarjian H, Talpaz M, et al: A phase I study of the combination of gleevec (imatinib mesylate) with low dose Ara-C. Blood 98:845a, 2001 (suppl 1, abstr)
9. Druker BJ, for the IRIS (International Randomized IFN vs. STI571) Study Group: STI571 (Gleevec/Glivec, imatinib) versus interferon (IFN) + cytarabine as initial therapy for patients with CML: Results of a randomized study. Proc Am Soc Clin Onc 21:1a, 2002 (abstr)
10. Druker BJ, Lydon NB: Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105:3-7, 2000
11. Druker BJ, Sawyers CL, Capdeville R, et al: Chronic myelogenous leukemia. Hematology (Am Soc Hematol Educ Program) 87-112, 2001
12. Druker BJ, Sawyers CL, Kantarjian H, et al: Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042, 2001
13. Druker BJ, Talpaz M, Resta D, et al: Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
14. Druker BJ, Tamura S, Buchdunger E, et al: Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells. Nat Med 2:561-566, 1996
15. Fang G, Kim CN, Perkins CL, et al: CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 96:2246-2253, 2000
16. Gambacorti-Passerini C, le Coutre P, Mologni L, et al: Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 23:380-394, 1997
17. Gatto SR, Scappini B, Verstovsek S, et al: In vitro effects of PS-341 alone and in combination with STI571 in Bcr-Abl positive cell lines both sensitive and resistant to STI571. Blood 98:101a, 2001 (suppl 1, abstr)
18. Graham SM, Jorgensen HG, Allan E, et al: Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99:319-325, 2002
19. Hochhaus A, Kreil S, Corbin AS, et al: Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16:2190-2196, 2002
20. Hofmann WK, Jones LC, Lemp NA, et al: Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 99:1860-1862, 2001
21. Holtz MS, Slovak ML, Zhang F, et al: Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 99:3792-3800, 2002
22. Hoover RR, Mahon FX, Melo JV, et al: Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 100:1068-1071, 2002
23. Kano Y, Akutsu M, Tsunoda S, et al: In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97:1999-2007, 2001
24. Kantarjian H, Jorge C, O'Brien S, et al: High rates of early major and complete cytogenetic responses with imatinib mesylate therapy given at 400 mg or 800 mg orally daily in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Proc Am Soc Clin Oncol 21:261a, 2002 (abstr)
25. Kantarjian H, Sawyers C, Hochhaus A, et al: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645-652, 2002
26. Klejman A, Rushen L, Morrione A, et al: Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene 21:5868-5876, 2002
27. La Rosée P, Johnson K, Moseson EM, et al: Preclinical evaluation of the efficacy of STI571 in combination with a variety of novel anticancer agents. Blood 98:839a, 2001 (suppl 1, abstr)
28. La Rosee P, Johnson K, O'Dwyer ME, et al: In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol 30:729-737, 2002
29. La Rosee P, O'Dwyer ME, Druker BJ: Insights from preclinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: A translational perspective. Leukemia 16:1213-1219, 2002
30. le Coutre P, Mologni L, Cleris L, et al: In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 91:163-168, 1999
31. Lugo TG, Pendergast AM, Muller AJ, et al: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247:1079-1082, 1990
32. Marley SB, Davidson RJ, Goldman JM, et al: Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia. Br J Haematol 116:162-165, 2002
33. Mow BM, Chandra J, Svingen PA, et al: Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood 99:664-671, 2002
34. Nimmanapalli R, Porosnicu M, Nguyen D, et al: Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Clin Cancer Res 7:350-357, 2001
35. O'Brien SG, Vallance SE, Craddock C, et al: PEGIntron and STI571 combination evaluation study (PISCES) in chronic phase chronic myeloid leukaemia. Blood 98:846a, 2001 (suppl 1, abstr)
36. O'Dwyer ME, Mauro MJ, Kurilik, G, et al: The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 100:1628-1633, 2002
37. O'Dwyer ME, Mauro MJ, Kuyl J, et al: Preliminary evaluation of the combination of imatinib mesylate (Gleevec) in combination with low dose interferon-alpha for the treatment of chronic phase CML. Blood 98:846a, 2001 (suppl 1, abstr)
38. Okuda K, Weisberg E, Gilliland DG, et al: ARG tyrosine kinase activity is inhibited by STI571. Blood 97:2440-2448, 2001
39. Ottmann OG, Druker BJ, Sawyers CL, et al: A phase II study of imatinib mesylate (Glivec) in patients with relapsed or refractory Philadelphia chromosome positive acute lymphoid leukemias. Blood 100:1965-1971, 2002
40. Porosnicu M, Nimmanapalli R, Nguyen D, et al: Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Bcr-Abl-positive acute leukemia cells. Leukemia 15:772-778, 2001
41. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al: Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100:1014-1018, 2002
42. Sawafuji K, Miyakawa Y, Weisberg E, et al: Effects of aminopeptidase inhibitors on STI571 resistant cell lines. Blood 98:309a, 2001 (suppl I, abstr)
43. Sawyers CL, Hochhaus A, Feldman E, et al: Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: Results of a phase II study. Blood 99:3530-3539, 2002
44. Shah NP, Nicoll JM, Nagar B, et al: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117-125, 2002
45. Sun X, Layton JE, Elefanty A, et al: Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL-expressing cells, demonstrating synergy between AG490 and STI571. Blood 97:2008-2015, 2001
46. Talpaz M, Silver RT, Druker BJ, et al: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 99:1928-1937, 2002
47. Thiesing JT, Ohno-Jones S, Kolibaba KS, et al: Efficacy of an Abl tyrosine kinase inhibitor in conjunction with other antileukemic agents against Bcr-Abl positive cells. Blood 96:3195-3199, 2000
48. Topaly J, Schad M, Zeller WJ, et al: Strong synergism of different signal transduction inhibitors in chronic myelogenous leukemia. Blood 98:617a, 2001 (suppl 1, abstr)
49. Topaly J, Zeller WJ, Fruehauf S: Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 15:342-347, 2001
50. van Oosterom AT, Judson I, Verweij J, et al: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358:1421-1423, 2001
51. Vigneri P, Wang JY: Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 7:228-234, 2001
52. von Bubnoff N, Schneller F, Peschel C, et al: BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: A prospective study. Lancet 359:487-491, 2002
53. Yu C, Krystal G, Varticovksi L, et al: Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res 62:188-199, 2002